The Scripps Research Institute

Gabriela Mustata Wilson

Theodore M Kamenecka

Paul David Robbins

Laura J Niedernhofer

The invention is directed to a method of inhibiting, within a living cell, the interaction between NF-&#x3ba;B essential modulator ('NEMO') with I&#x3ba;B kinase-&#x3b2; (IKK-&#x3b2;) at the NEMO binding domain (NBD), comprising exposing the cell to an effective amount or concentration of a compound of the invention, a NEMO-binding domain analog (NBDA). The invention is further directed to a method of treating a condition in a patient, wherein inhibiting the interaction between NF-&#x3ba;B essential modulator ('NEMO') with I&#x3ba;B kinase-&#x3b2; (IKK-&#x3b2;) at the NEMO binding domain (NBD) is medically indicated, comprising administering to the patient an effective dose of a compound of the invention. Conditions that can be treated by a method of the invention includes muscular dystrophy, asthma, inflammatory bowel disease, multiple sclerosis, Parkinson's Disease, arthritis, diabetes, graft versus host disease, accelerated aging, heart ischemia, cancer, UV-induced skin damage, or an age-related pathology.

Growing community of inventors

Evansville, IN, United States of America

Gabriela Mustata Wilson